Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Metastasis From Malignant Tumor Of Colon
Explore 33 assets in Metastasis From Malignant Tumor Of Colon →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Campania Luigi Vanvitelli
Modality
unclassified
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05468892CT.gov Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastasis From Malignant Tumor Of Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 (this asset) | University of Campania Luigi Vanvitelli | P2 | B · 57 |
| Fruquintinib | Peking University | P3 | BBB |
| Dexasone | Fudan University | P3 | BB |
| Oxaliplatin | Fudan University | P4 | BB |
| Irinotecan | Jun Huang | P3 | BB |
| Capecitabine | Jun Huang | P3 | BB |
| Cetuximab | Shanghai 6th People's Hospital | P3 | BB |
| Floxuridine | Fudan University | P3 | BB |
| ip-001 | Immunophotonics, Inc. | P2/3 | BB |
+42 more in the Metastasis From Malignant Tumor Of Colon cohort
Other indications for Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P3 | B · 57 |
| Anal Carcinoma | — | P1/2 | CCC · 48 |
| Anal Squamous Cell Carcinoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 in Metastasis From Malignant Tumor Of Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trifluridinetipiracil-hydrochloride-combination-agent-tas-102-metastasis-from-malignant-tumor-of-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →